Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Identify which cards provide flexible rewards without any fees. Compare your options for optimal rewards.
26,016 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
SCHD will conduct its annual reconstitution on March 23, trimming energy exposure and leaning more on financials to d...
Nebius inked a $27 billion AI infrastructure deal with Meta, locking in vast capacity and signaling its edge in the n...
A venture-backed biotech startup unveils a plan to collect genomic data from 100 million species to fuel AI drug disc...
Investors debate timing as IREN plans a bold AI expansion after a major capital raise. This guide breaks down the pla...
Tether plans a full-scale audit of USDT reserves by a Big Four firm, moving from attestations to a formal audit and s...
The Trek CEO’s daily routine fuses a lifelong love of reading with a belief that business should serve society, not j...
Lightstone unveils access to 25,000+ multifamily units as rent growth accelerates in markets with tight supply, shapi...
Claude’s unexpected nudge to sleep mid-chat has sparked a wave of online chatter and concern about AI reliability. Th...
Mortgage rates surge past 6.7% as bond markets wobble and geopolitics stoke inflation fears. Borrowers and lenders ad...
When Nvidia posts a blowout quarter, investors often wonder if the stock remains a smart buy. This article weighs his...
Market chatter surrounding SpaceX’s potential June 12 IPO reignites talk that Elon Musk could become the world’s firs...